This is not the most recent version of the article. View current version (6 DEC 2013)

Intervention Protocol

Rituximab for relapsing-remitting multiple sclerosis

  1. Dian He2,
  2. Hongyu Zhou1,*,
  3. Wenjie Han1,
  4. Shihong Zhang1

Editorial Group: Cochrane Multiple Sclerosis Group

Published Online: 11 MAY 2011

Assessed as up-to-date: 9 MAR 2011

DOI: 10.1002/14651858.CD009130

How to Cite

He D, Zhou H, Han W, Zhang S. Rituximab for relapsing-remitting multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 5. Art. No.: CD009130. DOI: 10.1002/14651858.CD009130.

Author Information

  1. 1

    West China Hospital, Sichuan University, Department of Neurology, Chengdu, Sichuan, China

  2. 2

    Affiliated Hospital of Guiyang Medical College, Department of Neurology, Guiyang, Guizhou Province, China

*Hongyu Zhou, Department of Neurology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, China. Hyzhou98@yahoo.com.

Publication History

  1. Publication Status: New
  2. Published Online: 11 MAY 2011

SEARCH

This is not the most recent version of the article. View current version (06 DEC 2013)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The effectiveness and safety of rituximab alone or as add-on, versus placebo or other treatments for relapsing-remitting multiple sclerosis will be assessed.